MedTrace Logo

ASPIRE II. Supporting Antibiotic Stewardship in Primary Care Via POCT

NCT06981130 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2025-05-20

No results posted yet for this study

Summary

Acute Respiratory Infections (ARIs) are a major contributor to antibiotic resistance, largely due to the over prescription of antibiotics driven by the subjective nature of clinical assessment. The ASPIRE II study aims to evaluate whether a Point-of-Care (POC) diagnostic test, utilising C-reactive protein (CRP) and Myxovirus resistance protein A (MxA) biomarkers to differentiate between viral and bacterial infections can support clinical decision-making and serve as an effective antimicrobial stewardship tool.

Conditions

  • Acute Respiratory Infection

Interventions

DEVICE

FebriDx Point of Care Test

Patients self-referring to their GP practice with symptoms of acute respiratory infection (ARI) will receive the FebriDx point-of-care test during their clinical consultation.

Sponsors & Collaborators

  • Cwm Taf University Health Board (NHS)

    collaborator OTHER_GOV

  • University of South Wales

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-06-01
Completion
2024-12-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06981130 on ClinicalTrials.gov